Subscribe to Newsletter

Discovery & Development

Discovery & Development Drug Discovery

The Evolution of HIV/AIDS Treatment

| Jamie Irvine | 6 min read

In light of cabotegravir’s positive opinion for sexually acquired HIV-1, I wanted to explore the history and politics of HIV/AIDS drug development

Discovery & Development Drug Discovery

Nobel Prize for mRNA COVID-19 Vaccine Technology

| Stephanie Vine | 7 min read

Katalin Karikó and Drew Weissman win prestigious prize for persevering in a field that many ignored.

Discovery & Development Drug Discovery

The FLEET of Hope

| Robert H Cichewicz | 3 min read

Fungal infections and antifungal resistance are a significant problem; here’s one approach to consider

Discovery & Development Drug Discovery

Meet an AI Model that Predicts Teratogenicity

| Jamie Irvine | 3 min read

Researchers demonstrate that complex data analysis paired with artificial intelligence can predict additional causes of Teratogenicity

Discovery & Development Drug Discovery

CRISPR With Caution

| Rob Coker | 3 min read

Deputy editor Rob Coker recalls his trip to the labs of Caszyme, Vilnius, where he spoke with CEO Monika Paule about the potential of genome editing

Discovery & Development Drug Discovery

Addressing Alzheimer’s

| 3 min read

The more we learn about the complexity of Alzheimer’s, the more we need to change the way we treat it

Discovery & Development Drug Discovery

Alzheimer’s Treatment Timeline

| Stephanie Vine | 2 min read

With new drugs showing promise for Alzheimer’s, is the drug development drought over?

Discovery & Development Drug Discovery

Fabulously Interesting

| 6 min read

Sitting Down With… Sharon L Rogers, AmyriAD CEO, Renowned drug developer, 2023 Power Lister, and Olympic figure skating official

Discovery & Development Clinical Trials

Ignaz Semmelweis, We Salute You

| Rob Coker | 4 min read

In the second episode of the We Salute You series, we focus on much maligned Hungarian physician Ignaz Semmelweis

Discovery & Development Drug Discovery

Llamas Versus Dengue

| Stephanie Vine | 3 min read

Why one company is focusing on camelid-derived antibodies to tackle dengue.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register